A systematic review and meta-analysis of OCT-based ophthalmic changes in amyotrophic lateral sclerosis.

J NeuroimmunolJul 24, 2026 (epub)
Clinical ResearchNeurologyOphthalmology

Asmar Ahsan, Ju-Chi Ou, Pritha Majumder et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated optical coherence tomography (OCT) findings in amyotrophic lateral sclerosis (ALS) patients. The analysis included 17 studies and found a significant reduction in retinal nerve fiber layer (RNFL) thickness in ALS patients compared to healthy controls, with an unadjusted standardized mean difference (SMD) of -0.295 (95% CI: -0.522, -0.068).

Key findings

  • Significant reduction of RNFL thickness in ALS patients compared to controls (SMD = -0.295, 95% CI: -0.522, -0.068).
  • RNFL thinning was particularly pronounced in spinal-onset ALS (SMD = -0.54, 95% CI: -0.98, -0.10).
  • Statistical significance for RNFL and macular thinning was observed only in the non-Asian subgroup.

Why it matters

The findings suggest that OCT may serve as a useful biomarker for detecting retinal neurodegeneration in ALS, potentially aiding in the assessment of disease progression and monitoring.

Source

PubMed · PMID 42526365

Published in J Neuroimmunol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.